Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase 3 9Phase NA 2Phase 2/3 2Phase 1/2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Carcinoma, Non-Small-Cell Lung 10Squamous Cell Carcinoma of Head and Neck 8Neoplasms 6Stomach Neoplasms 5Prostatic Neoplasms 5Lung Neoplasms 5Head and Neck Neoplasms 5Oropharyngeal Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Fatigue 4Urinary Bladder Neoplasms 3Recurrence 3Ovarian Neoplasms 3Neoplasm Metastasis 3Myasthenia Gravis 3Mouth Neoplasms 3Leukemia, Myeloid, Acute 3Colorectal Neoplasms 3Weight Loss 2Peritoneal Neoplasms 2Pancreatic Neoplasms 2Nasopharyngeal Carcinoma 2Melanoma 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Glioblastoma 2Fallopian Tube Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Squamous Cell 2

Interventions

Platinum 2Cisplatin 21,2-diaminocyclohexaneplatinum II citrate 2dehydroftorafur 1atezolizumab 1Watchful Waiting 1Taxes 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Gemcitabine 1Fluorouracil 1Docetaxel 1Disulfides 1Cetuximab 1Carboplatin 1Bevacizumab 1(225)Ac-DOTA-c(RGDyK) 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Nasopharyngeal Carcinoma × 30 days × Clear all
NCT05063552 2026-05-13

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT02135042 2026-05-07

Individualized Treatment Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

NRG Oncology

Phase 2/3 Active not recruiting
685 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡